Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


The clinical landscape for AAV gene therapies

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 20, 173-174 (2021)



The authors thank R. Kerr (University of Oxford), A. Bersenev (Yale University) and D. M. Kullmann (University College London) for their input into the study design and discussion of the dataset.

Supplementary Information

  1. Supplementary Figures
  2. Supplementary Table 1

Competing Interests

D.A.K. is a non-executive director of Redpin Therapeutics, which develops AAV gene therapies. O.P.S. is a non-executive director of SparingVision SA, which develops AAV gene therapies. J.C.M. vdL is a consultant to 4BIO Capital. The other authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links